Novartis enlists Microsoft to modernize drugs' path to market

Novartis
Novartis has tapped Microsoft's artificial intelligence prowess to advance its drug development platforms from discovery to manufacturing to marketing. (Novartis)

Novartis’ new collaboration with Microsoft leverages artificial intelligence to streamline drug discovery, but the joint effort goes beyond just finding new treatments faster.

From research and manufacturing to clinical trials and marketing, Microsoft’s AI technology will impact Novartis’ entire medicine path to market. Everyone, even those without data science training, will be able to use the solutions to cull Novartis data troves.

“There’s value for every person in the organization to share data, to connect to each other, beyond the research and discovery to manufacturing, even to marketing,” Peter Lee, Microsoft's corporate vice president for AI and research, said in an intro video.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

RELATED: Novartis puts AI on the job to help reps say the right things to the right doctors

The way Novartis sees it, the company is on a path to becoming a “data science company,” Shahram Ebadollahi, Novartis' global head of data science, said by email. And the Microsoft deal figures importantly into that corporate mission. After all, what better way to drive substantial change—and get a jump on competing pharma companies also trying to figure out how to use their reams of health data—than to partner with the original vanguard of tech companies?

The two companies had worked together previously and went through many months of exploration before announcing the deal, Ebadollahi said. It is a “true 50-50 collaboration,” he added.

Novartis is not new to the use of AI, but this collaboration expands beyond previous efforts. Along with revamp of the drug discovery process, for instance, Novartis will use Microsoft AI to review the clinical data from hundreds of its drug studies over the past two decades. The project, called Data42, will mine 2 million patient years of clinical trial data to attempt to uncover new insights, Ebadollahi said.

RELATED: Novartis' Sandoz goes digital from back office to 'not just apps,' therapeutics

“The synergy between Novartis’ global leadership in innovative medicines and Microsoft’s leadership position in Cloud and AI will help us deliver a fundamental transformation in healthcare,” he said. “Together, we will empower the work of healthcare professionals and address some of society’s most challenging healthcare issues for the benefit of as many people as possible.”

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.